Congratulations to our own Martin Zarka, Ph.D. for being profiled by his alma mater. The University of New South Wales, School of Biotechnology and Biomolecular Sciences spotlighted Martin’s groundbreaking work in its series, Ph.D. Stories. The article describes Martin’s role in developing Glyteine®, alongside his supervisor, Associate Professor Wallace Bridge, Ph.D.
Glyteine® is a proprietary form of gamma-glutamylcysteine (GGC), the precursor to glutathione. Martin was instrumental in developing the ingredient, which has been shown to increase cellular glutathione levels within hours after a single dose.
Martin and Wallace achieved a patent, enabling them to commercialize their technology. Introduced to the market less than a year ago, Glyteine® and the first commercial product to contain it, Continual-G®, are already earning international attention from the nutrition and dietary supplement communities.
We are proud that Martin Zarka, Ph.D. continues to provide us with superb innovation and leadership in his role as Research & Development Manager at our Newcastle facility.
Read the article: https://www.babs.unsw.edu.au/experience/phd-profiles/dr-martin-zarka